Form 4: Corbus CEO Sells Shares After Option Exercise

Corbus Pharmaceuticals CEO Yuval Cohen exercised stock options and subsequently sold shares totaling 27,633 under a pre-arranged 10b5-1 trading plan.

Summary

• Corbus Pharmaceuticals Holdings, Inc. CEO and Director, Yuval Cohen, reported transactions involving the exercise of stock options and the subsequent sale of common stock.
• On October 24, 2025, Mr. Cohen acquired 18,660 shares of common stock by exercising stock options at a price of $4.26 per share.
• Immediately following the option exercise on October 24, 2025, Mr. Cohen sold 18,660 shares of common stock at a weighted average price of $17.01 per share, with individual sales ranging from $16.79 to $17.38.
• On October 27, 2025, Mr. Cohen acquired an additional 8,973 shares of common stock by exercising stock options at a price of $4.26 per share.
• Following this exercise on October 27, 2025, Mr. Cohen sold 8,973 shares of common stock at a weighted average price of $17.14 per share, with individual sales ranging from $17.00 to $17.31.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Cohen on March 14, 2025.
• After these transactions, Mr. Cohen beneficially owns 138,187 shares of common stock, which includes 123,561 unvested Restricted Stock Units (RSUs).
• The stock options exercised were part of an annual award made under the issuer's 2014 Equity Compensation Plan, with 25% vesting on February 13, 2024, and the remaining 75% vesting in equal monthly installments over 36 months commencing March 13, 2024, and expiring on February 13, 2033.
• Following the exercises, Mr. Cohen beneficially owns 22,106 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (option exercise and sale) under a pre-arranged 10b5-1 plan. While profitable for the insider, the sale of shares could be viewed neutrally to slightly negatively by the market, but it's a common practice for executives to diversify holdings and realize gains from equity compensation.

Positives

• The CEO realized significant gains by exercising stock options at $4.26 and selling shares at weighted average prices of $17.01 and $17.14, indicating a profitable transaction for the insider.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which demonstrates a structured approach to insider trading and can mitigate concerns about opportunistic selling.

Negatives

• The sale of shares by the Chief Executive Officer, even under a 10b5-1 plan, could be perceived by some investors as a signal of reduced confidence or a desire to lock in gains rather than hold for future appreciation.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction; it is purely a report of insider transactions.

Management Comments

• The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025.
• The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan.

Industry Context

This filing reports routine insider transactions and does not provide information directly related to broader industry trends or competitive landscape. Insider trading activity is a common occurrence across all industries, often reflecting executive compensation structures and personal financial planning.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the CEO's sale of shares, even if planned, with varying interpretations, from a normal part of executive compensation to a potential signal of insider sentiment.
• Employees: The exercise and sale of options by the CEO highlight the value of equity compensation plans within the company.

Next Steps

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the reported ranges.

Key Dates

Recommendation

The filing details routine insider transactions by the CEO, involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. While the transactions were profitable for the insider, they do not provide sufficient new information to alter a fundamental investment thesis. The sale of shares, even if planned, might be viewed with slight caution by some investors, but it's a common practice for executives to diversify holdings and realize gains from equity compensation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a compelling reason for a significant change in investment strategy.

Keywords

Corbus Pharmaceuticals, CRBP, Yuval Cohen, Insider Trading, Form 4, Stock Options, 10b5-1 Plan, CEO, Share Sale, Equity Compensation